Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VSV-EBOPLUS

Financiado

Cerrado

SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE...

SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE Sofia ref. 116068 The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the... ver más

31/03/2023

TLS-S

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-03-31

IMI2-2015-08-01: Ebola and other filoviral haemorrha...

I+D

Cerrada hace 8 años

0% 55% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

TLS-S

1.51M€ | Lider

UNISI

1.65M€ | Participante

MBT

485.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VSV-EBOVAC Vaccine safety and immunogenicity signatures of human respon... 5M€ Cerrado

EBOVAC1 Development of a Prophylactic Ebola Vaccine Using an Heterol... 98M€ Cerrado

EBO-PEP The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis,... 3M€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterol... 51M€ Cerrado

SAF2008-02036 BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT... 655K€ Cerrado

Duración del proyecto: 69 meses Fecha Inicio: 2017-06-12
Fecha Fin: 2023-03-31

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine take, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US). Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children. We propose: 1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOV;

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores